Key result
Isoleucine and proline mutations at position 100 of the EMCV VP1 protein significantly increased survival rates to 60% compared to 0% for wild-type virus in mice.
Absolute Event Rate: 60% vs 0%
p-value: p=<0.0001
A point mutation at position 100 of VP1 in Encephalomyocarditis virus alters its in vivo pathogenicity in mice, with specific amino acid substitutions significantly reducing mortality and brain damage.
Viable EMCV VP1 mutants enable targeted virulence studies; leaves open clinical translation to myocarditis.
Encephalomyocarditis virus (EMCV) infection leads to many diseases including encephalitis, myocarditis and diabetes in its natural host, the mouse. In this study, we generated four cDNA clones with a point mutation at position 100 of VP1. The amino acids isoleucine, alanine, serine and proline were substituted with threonine in the four different clones of EMCV strain BJC3 by site-specific mutagenesis, and viable viruses were rescued. Although all mutants and wild-type viruses display different plaque morphologies, they replicate comparably in BHK-21 cells. The pathogenicity of the mutated viruses was systematically analyzed to investigate the importance of this amino acid in the viral pathogenicity and disease phenotype of EMCV infection in mice. The results showed that the isoleucine- (T1100I) and proline-mutated viruses (T1100P) exhibited a reduced mortality, lower cerebral virus loads and alleviated brain damage while the viruses with serine (T1100S) and alanine (T1100A) substitutions displayed similar properties as the wild-type virus. These findings indicate that the amino acid at position 100 of VP1 is important for EMCV in vivo infection, and its mutation alters the pathogenicity of viral infection in mice.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2011) studied Encephalomyocarditis virus (EMCV) infection (n=60). EMCV VP1 position 100 mutations (T1100I and T1100P) vs. Wild-type EMCV (RvBJC3W) was evaluated on Survival rate at 2 weeks (p=<0.0001). Isoleucine and proline mutations at position 100 of the EMCV VP1 protein significantly increased survival rates to 60% compared to 0% for wild-type virus in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: